Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Illumina (ILMN) Strong on Product Launches, Competition Rife
by Zacks Equity Research
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.
Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
by Zacks Equity Research
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.
Abbott's Ellipse ICD Receives FDA Approval for MRI Scans
by Zacks Equity Research
Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.
Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm
by Zacks Equity Research
Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.
Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI
by Zacks Equity Research
Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.
Abiomed's Latest Regulatory Progress Boosts Impella Line
by Zacks Equity Research
We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.
4 Top MedTech Stocks for Dividend Investors in 2017
by Zacks Equity Research
Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
by Zacks Equity Research
Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.
Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
by Zacks Equity Research
Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.
Agilent (A) Sues Former Employees for Infringing IP Rights
by Zacks Equity Research
Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.
Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Abbott Laboratories (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
Profit from the Dollar's Dip with These 5 S&P 500 Stocks
by Swarup Gupta
Companies with significant overseas exposure stand to gain from the dollar's dip.
Company News for July 21, 2017
by Zacks Equity Research
Companies In The News are: ABT,KMI,PM,TRV
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales
by Zacks Equity Research
Abbott Laboratories (ABT) gains on strong Q2 performance. Raised guidance buoys optimism.
The Hottest Earnings Charts of the Week
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing it.